Magnesium doping alters structural and magnetic properties in perovskite oxides, indicating potential applications.
Perovskite-type (ABO3−δ) oxides provide a versatile platform to explore charge–spin–orbital–lattice interactions with wide-ranging technological applications. In this work, magnesium-doped Ba(Mn1−xMgx)O3−δ (x = 0–0.08) oxides were synthesized via a cost-effective sol–gel route using metal nitrates and oxalic acid precursors. It exhibits a hexagonal structure (space group R 3̄ m) for undoped (x = 0) and dual “hexagonal + orthorhombic” phases for magnesium-doped oxides for x = 0.02–0.08. The lattice parameters of the hexagonal phase decrease with magnesium content (x) as ah = bh ~ 5.714 Å, ch ~ 21.472 Å (ar ~ 7.881, α ~ 42.51° in rhombohedral axis) for {x = 0} to ah = bh ~ 5.708 Å, ch ~ 21.450 Å (ar ~ 7.878, α ~ 42.53° in rhombohedral axis) for {x = 0.08}, accompanied by total cell volume reduction. Similarly, the orthorhombic unit cell volume decreases (~876.2–866.3 Å3) with magnesium substitution due to charge compensation, while the average bond length increases (~2.639–2.910 Å), indicating lattice distortion. These structural changes confirm the incorporation of Mg2+ into the lattice and its influence on the crystal framework. Raman peak at ~318.7 cm−1 (for x = 0) shifted toward lower wavenumber side along with the decrease in peak intensity. Bands, in the 550–800 cm-1 range, are attributed to A1g symmetric stretching of BO6 octahedra and oxygen vacancy-related modes, confirming octahedral distortions. The M–H curves display narrow hysteresis with low Hc (~61–76 Oe) and Mr (~9.3–10.7 × 10−4 emu/g), confirming the absence of long-range ferromagnetism. The saturation magnetization decreases sharply with Mg2+ substitution due to disrupted Mn–Mn exchange, but partially recovers at higher doping (x = 0.08) owing to stabilization of mixed Mn3+/Mn4+ states via oxygen non-stoichiometry. Presence of anion vacancies and related properties suggests the material’s suitability for technological applications, e.g., fuel cells, catalyst, and membrane.
No takes yet. Share an insight, caveat, or question.
Bharatee et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: